|Bid||176.30 x 0|
|Ask||176.30 x 0|
|Day's range||171.30 - 176.50|
|52-week range||127.10 - 245.40|
|Beta (5Y monthly)||0.58|
|PE ratio (TTM)||17.82|
|Earnings date||10 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||192.13|
(Bloomberg) -- AstraZeneca Plc effectively blocked a $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker from a buyout offer by Advent International and Singapore wealth fund GIC, according to people familiar with the situation.Most Read from BloombergThe Hot New Trend For Hedge Funds Is—Finally—Female Founders‘Ghost Signs’ Haunt London’s Reviving NeighborhoodsReliving the New York Subway Map DebateAutomating the War on Noise PollutionChina Cash Flow
Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.
Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.